ライフサイエンスコーパス: subretinal fluid

1 istent fluid by fluid type (intraretinal and subretinal fluid).

2 was there disturbance of the inner retina or subretinal fluid.

3 pigment) and free fluorophores within fresh subretinal fluid.

4 macular schisis, cystoid macular edema, and subretinal fluid.

5 All 9 tumors were associated with shallow subretinal fluid.

6 3 months or until the complete resolution of subretinal fluid.

7 subretinal vacuum and facilitating increased subretinal fluid.

8 treoretinopathy, and delayed reabsorption of subretinal fluid.

9 teen tumors (86%) had complete resolution of subretinal fluid.

10 he optic disc pit and evaluate the source of subretinal fluid.

11 esis of cerebrospinal fluid as the source of subretinal fluid.

12 with the presence of previous or persistent subretinal fluid.

13 re used to evaluate MEK inhibitor-associated subretinal fluid.

14 antly associated with previous or persistent subretinal fluid.

15 amcinolone acetonide, with resolution of the subretinal fluid.

16 etached than when only 1 quadrant (0.8%) had subretinal fluid.

17 were bilateral retinoblastoma and absence of subretinal fluid.

18 ess on B-scan ultrasonography (63% vs. 84%), subretinal fluid (58% vs. 90%), and orange pigment (50%

19 (8%, 20%, 38%, and 39%; P<0.001), associated subretinal fluid (64%, 80%, 82%, and 83%; P<0.001), intr

20 38%) configuration, and displayed associated subretinal fluid (85%).

21 choroid vessels underneath the retina cause subretinal fluid accumulation and retinal detachment.

22 se that these changes may be attributable to subretinal fluid accumulation in our novel retinal detac

23 a vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in th

24 , 2.4; CI, 1.7-3.6) versus </=75 mum, foveal subretinal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subre

25 remain unclear, lead to the accumulation of subretinal fluid and autofluorescent waste products from

26 t reproducibility, particularly in eyes with subretinal fluid and greater choroidal thickness.

27 njection due to the presence of intraretinal/subretinal fluid and pigment epithelial detachment (PED)

28 he intense hyperfluorescence group with both subretinal fluid and posterior retinal cystoid degenerat

29 f the eyes had subretinal fluid only or both subretinal fluid and posterior retinal cystoid degenerat

30 The resolution of the subretinal fluid and recurrence rates were assessed in r

31 ing vitreous seed regression were absence of subretinal fluid and subretinal seeds.

32 solved after delivery with regression of the subretinal fluid and the disappearance of subfoveal exud

33 ness (CMT), and the presence of intraretinal/subretinal fluid and the height and presence of PED were

34 raster scans were evaluated for intraretinal/subretinal fluid and, when applicable, vitreomacular tra

35 ad well-circumscribed vessels, 86% (6/7) had subretinal fluid, and 14% (1/7) had intraretinal fluid.

36 Poorly circumscribed vessels, subretinal fluid, and intraretinal fluid each were seen

37 of a retinal detachment by the injection of subretinal fluid, and intravitreal injection of green fl

38 cysts, epiretinal membranes, microaneurysms, subretinal fluid, and outer layer disruption/reflectivit

39 with gradual resolution of intraretinal- and subretinal fluid, and remained stable in 12 months.

40 ponse depended on baseline BCVA, presence of subretinal fluid, and retinal angiomatous proliferation,

41 scan for the presence of intraretinal fluid, subretinal fluid, and sub-retinal pigment epithelium flu

42 inal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subretinal fluid, and subretinal hyperreflective materia

43 hickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual

44 Alterations of the OS overlying lesions with subretinal fluid are similar to those seen in central se

45 out persistent fluid (cystic intraretinal or subretinal fluid at all 4 initial visits).

46 In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, si

47 thickness (CMT), the number of patients with subretinal fluid at each follow-up time, the number of p

48 with intermediate hyperfluorescence had only subretinal fluid at OCT and a dry macula was obtained in

49 for creation of a permanent intraretinal and subretinal fluid barrier.

50 a shallow decline in acuity with increasing subretinal fluid but a much steeper decline with equival

51 escence from lipofuscin within RPE and fresh subretinal fluid, but when choroidal haemangioma is chro

52 s causes of retinal fluid, but was worst for subretinal fluid compared to intraretinal or sub-retinal

53 b-treated eyes had resolved intraretinal and subretinal fluid compared with aflibercept-treated eyes.

54 /= 20/40) except in a single patient in whom subretinal fluid developed under the fovea.

55 ous, rather than intermittent, monitoring of subretinal fluid drainage via indirect ophthalmoscopy.

56 d to the area with neovascularization and no subretinal fluid drainage was performed.

57 External drainage of subretinal fluid during scleral buckling procedures is c

58 half-dose group had at least 1 recurrence of subretinal fluid during the follow-up.

59 The subretinal fluid foci associated with MEK inhibitors hav

60 hibit recurrent or resistant intraretinal or subretinal fluid following multiple injections with eith

61 han 3 mm in size, macular location, or minor subretinal fluid; group C = retinoblastoma with localize

62 Infants with bilateral subretinal fluid had an older gestational age compared w

63 The mean maximum subretinal fluid height decreased from 126.6 mum at enro

64 Central subfield thickness, maximum subretinal fluid height, and maximum pigment epithelial

65 Changes in maximum subretinal fluid height, maximum pigment epithelial deta

66 age, larger tumor, and greater incidence of subretinal fluid, hemorrhage, and extraocular extension.

67 caused by bilateral patching on the flow of subretinal fluid in a physical model of retinal detachme

68 ol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despi

69 , controversy exists regarding the source of subretinal fluid in these cases.

70 asing subretinal hyperreflective material or subretinal fluid in this circumstance reduces vision fur

71 3 %) pigment epithelial detachment, 6 (55 %) subretinal fluid, in 29 (39 %) eyes regardless of the le

72 The percentage of patient visits with no subretinal fluid increased from 0.5% to 41% after the in

73 s plana vitrectomy, external drainage of the subretinal fluid, intraoperative systemic hypertension,

74 ated with signs of active myopic CNV (either subretinal fluid/intraretinal cysts on SD OCT or dye lea

75 depigmentation area, subretinal haemorrhage, subretinal fluid, macula thickness, macular scar, subret

76 estational age compared with infants without subretinal fluid (median, 40.4 vs 39.1 weeks, respective

77 orrhage (n = 2), retinal hemorrhage (n = 4), subretinal fluid (n = 4), and/or intraretinal exudation

78 OCT characteristics included subretinal fluid (n = 5), intraretinal fluid and cysts (

79 pigment epithelial alterations (n = 9; 53%), subretinal fluid (n = 5; 29%), and orange pigment (n = 3

80 Associated features included subretinal fluid (n = 6), subretinal exudation (n = 6),

81 Related features included subretinal fluid (n = 9; 19%), cystoid retinal edema (n

82 The presence of subretinal fluid (odds ratio [OR], 1.98; 95% confidence

83 We evaluated VEGF and HGF protein levels in subretinal fluid of eyes with ROP, and expression of the

84 rs (68.5% vs. 55.3%; P = 0.003), and to have subretinal fluid on OCT (86.7% vs. 81.0%; P = 0.047).

85 Median time to complete resolution of subretinal fluid on OCT was 3.7 weeks (range, 2-12 weeks

86 al foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 an

87 dilated retinal examination, 1 of which had subretinal fluid on SD OCT.

88 cence group, 82.6% and 17.4% of the eyes had subretinal fluid only or both subretinal fluid and poste

89 In the intense hyperfluorescence group with subretinal fluid only, a dry macula was obtained in 89.5

90 follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal neovascularisat

91 indication was recurrence of intraretinal or subretinal fluid or new hemorrhage.

92 reatment criteria relying on intraretinal or subretinal fluid or new hemorrhages may be expanded to i

93 tion of fluid in the neuroepithelium, namely subretinal fluid or posterior retinal cystoid degenerati

94 y (BCVA) at baseline (P = .001), presence of subretinal fluid (P = .001), and retinal angiomatous pro

95 mor thickness (P = .001) and the presence of subretinal fluid (P = .05), and the only factor predicti

96 increasing tumor thickness (P = 0.010), and subretinal fluid (P = 0.001).

97 = 0.005), -0.200 (-1.20, 0.60) in cases with subretinal fluid (p = 0.207), 0.000 (-0.60, 0.30) in pig

98 ween the tumor and the optic disc (P=0.026), subretinal fluid (P=0.035), thickness of residual tumor

99 al RPE accumulation of lipofuscin as well as subretinal fluid, particularly on the fresh advancing tu

100 kness more than 2 mm, presence of associated subretinal fluid, presence of orange pigment on the tumo

101 not at 0.15 mM, also significantly enhanced subretinal fluid reabsorption (P < 0.05).

102 the development of INS37217 for stimulating subretinal fluid reabsorption in conditions that result

103 e results demonstrate that INS37217 enhances subretinal fluid reabsorption in experimental retinal de

104 In vivo INS37217 enhances the rates of subretinal fluid reabsorption in experimentally induced

105 tion of 1 mM INS37217 significantly enhanced subretinal fluid reabsorption when compared with vehicle

106 The mean time of the subretinal fluid resolution was significantly shorter in

107 t observed in the contralateral eye or after subretinal fluid resolution.

108 Subretinal fluid resolved in 13/18 eyes (72 %), and subr

109 Subretinal fluid resolved in 70% of pooled aflibercept-t

110 Subretinal fluid resolved in 81% by the last post-PDT vi

111 s mnemonic represent T (Thickness >2 mm), F (subretinal Fluid), S (Symptoms), O (Orange pigment), and

112 We examined subretinal fluid samples from eyes using rhegmatogenous

113 simultaneous measurement of 50 biomarkers in subretinal fluid samples obtained from patients who unde

114 acteristics and variations in a patient with subretinal fluid secondary to a carotid cavernous fistul

115 ee eyes with a closed hole showed persistent subretinal fluid (SRF) after gas absorption.

116 Subretinal fluid (SRF) and vitreous from patients with r

117 orrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence

118 e features in 24 of 30 eyes (80%), including subretinal fluid (SRF) in 20 of 30 eyes (67%) and retina

119 Hyper-AF corresponded to areas of subretinal fluid (SRF) on spectral-domain OCT and was fo

120 On OCT, subretinal fluid (SRF) was detected in 77% of CM patient

121 uantify intraretinal cystoid fluid (IRC) and subretinal fluid (SRF) was developed.

122 At baseline, subretinal fluid (SRF) was present in 57% of patients wi

123 resence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachmen

124 ed OCT, including intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen

125 changes, such as intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen

126 ns for presence of intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epitheli

127 l center point and intraretinal fluid (IRF), subretinal fluid (SRF), and subretinal pigment epitheliu

128 tina, pigment epithelial detachments (PEDs), subretinal fluid (SRF), and subretinal tissue (SRT).

129 wth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visua

130 ed visits where cystoid macular edema (CME), subretinal fluid (SRF), or pigment epithelial detachment

131 s included intraretinal cystoid fluid (IRC), subretinal fluid (SRF), pigment epithelial detachment, a

132 At 2 years, intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (

133 Intraretinal fluid (IRF), subretinal fluid (SRF), subretinal pigment epithelium fl

134 Changes in thickness/volume of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pig

135 ume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment e

136 smaller area of occult CNV, and presence of subretinal fluid (SRF).

137 disease activity (intraretinal cysts [IRC], subretinal fluid [SRF], diffuse retinal edema [DRE], ret

138 e impact on acuity of defined OCT changes in subretinal fluid, subretinal hyperreflective material, a

139 boundaries included the neurosensory retina, subretinal fluid, subretinal tissue, and pigment epithel

140 ineated by these boundaries included retina, subretinal fluid, subretinal tissue, and pigment epithel

141 of the left eye showed a geographic patch of subretinal fluid temporal to the macula that was associa

142 linically relevant disease features, such as subretinal fluid, that were missed by FP, and had a lowe

143 .49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 mu (aHR, 0.52; 95% CI,

144 on about CNV, CNV volume, retinal thickness, subretinal fluid volume and height of neurosensory detac

145 sis of clinically relevant features, such as subretinal fluid volume or pigment epithelial detachment

146 At 12 months, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated

147 ter PDT, complete control with resolution of subretinal fluid was achieved in 7 tumors (78%), with me

148 Subretinal fluid was associated with better VA.

149 successfully re-attached surgically and the subretinal fluid was gradually absorbed within three mon

150 Overlying subretinal fluid was identified by EDI OCT (16%), ophtha

151 Subretinal fluid was noted on follow-up examination to h

152 At 1 month a complete resolution of subretinal fluid was observed in 19 half-fluence-treated

153 vitreal bevacizumab until no intraretinal or subretinal fluid was observed on optical coherence tomog

154 revealed a thicker choroidal thickness when subretinal fluid was present as compared to that observe

155 Subretinal fluid was present in 71% of patients, and PVD

156 Subretinal fluid was present in all the predominantly cl

157 er subretinal tissue complex and presence of subretinal fluid were associated with less GA developmen

158 T), as well as associated features including subretinal fluid, were recorded before PDT and during fo

159 t or multiple recurrences of intraretinal or subretinal fluid while receiving monthly bevacizumab or

160 EDI-OCT disclosed macular subretinal fluid with an increase of choroidal thickness

161 al thinning overlying choroidal nevus; fresh subretinal fluid with preservation of photoreceptors ove

162 detachment (PED) in right eye and a cuff of subretinal fluid with underlying yellow deposits along s

163 underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6